UMMS Affiliation

Thompson Lab; Department of Biochemistry and Molecular Pharmacology

Publication Date

2018-12-06

Document Type

Article

Disciplines

Biochemistry | Enzymes and Coenzymes | Immune System Diseases | Immunity | Medicinal-Pharmaceutical Chemistry

Abstract

The peptidylarginine deiminases PAD2 and PAD4 are implicated in the pathogenesis of several autoimmune diseases. PAD4 may be pathogenic in systemic lupus erythematosus (SLE) through its role in neutrophil extracellular trap (NET) formation that promotes autoantigen externalization, immune dysregulation, and organ damage. The role of this enzyme in mouse models of autoimmunity remains unclear, as pan-PAD chemical inhibitors improve clinical phenotype, whereas PAD4-KO models have given conflicting results. The role of PAD2 in SLE has not been investigated. The differential roles of PAD2 and PAD4 in TLR-7-dependent lupus autoimmunity were examined. Padi4-/- displayed decreased autoantibodies, type I IFN responses, immune cell activation, vascular dysfunction, and NET immunogenicity. Padi2-/- mice showed abrogation of Th subset polarization, with some disease manifestations reduced compared with WT but to a lesser extent than Padi4-/- mice. RNA sequencing analysis revealed distinct modulation of immune-related pathways in PAD-KO lymphoid organs. Human T cells express both PADs and, when exposed to either PAD2 or PAD4 inhibitors, displayed abrogation of Th1 polarization. These results suggest that targeting PAD2 and/or PAD4 activity modulates dysregulated TLR-7-dependent immune responses in lupus through differential effects of innate and adaptive immunity. Compounds that target PADs may have potential therapeutic roles in T cell-mediated diseases.

Keywords

Autoimmune diseases, Autoimmunity, Inflammation, Lupus, Neutrophils

Rights and Permissions

Copyright © 2018 The American Society for Clinical Investigation. The JCI is an open access journal. Publisher PDF posted as allowed by the publisher's policy posted at https://www.jci.org/kiosks/terms.

DOI of Published Version

10.1172/jci.insight.124729

Source

JCI Insight. 2018 Dec 6;3(23):e124729. doi: 10.1172/jci.insight.124729. Link to article on publisher's site

Journal/Book/Conference Title

JCI Insight

Comments

Full author list omitted for brevity. For the full list of authors, see article.

Related Resources

Link to article in PubMed

PubMed ID

30518690

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.